Erythro Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 4.80 Cr
as on 23-10-2024
- Company Age 33 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.84 Cr
as on 23-10-2024
- Satisfied Charges ₹ 1.80 Cr
as on 23-10-2024
- Revenue -11.16%
(FY 2023)
- Profit -5.50%
(FY 2023)
- Ebitda -1.21%
(FY 2023)
- Net Worth 6.15%
(FY 2023)
- Total Assets 3.53%
(FY 2023)
About Erythro Pharma
The Corporate was formerly known as Lake View Labs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.80 Cr.
The company currently has active open charges totaling ₹9.84 Cr. The company has closed loans amounting to ₹1.80 Cr, as per Ministry of Corporate Affairs (MCA) records.
Duvvuru Abhiram, Rajagopala Duvvuru, and Balachandra Duvuru serve as directors at the Company.
- CIN/LLPIN
U24239TG1991PTC012286
- Company No.
012286
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Erythro Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajagopala Duvvuru  | Managing Director | 01-Jul-2003 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Duvvuru Abhiram | Director | 05-Feb-2018 | Current |
| Balachandra Duvuru | Director | 19-Jan-1998 | Current |
Financial Performance of Erythro Pharma.
Erythro Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.16% decrease. The company also saw a slight decrease in profitability, with a 5.5% decrease in profit. The company's net worth moved up by a moderate rise of 6.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Erythro Pharma?
In 2023, Erythro Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pavanasuta Renewable Energy Private LimitedActive 9 years 10 monthsDuvvuru Abhiram is a mutual person
- Agni Interactive Gaming Solutions Private LimitedActive 14 years 8 months
Duvvuru Abhiram is a mutual person
- Credence Imaging And Diagnostics Private LimitedActive 10 years 6 months
Duvvuru Abhiram is a mutual person
- United Radio-Imaging Services Private LimitedActive 9 years 9 months
Duvvuru Abhiram is a mutual person
- Threo Laboratories Private LimitedActive 33 years 3 months
Rajagopala Duvvuru and Balachandra Duvuru are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Jul 2007 | ₹6.89 Cr | Open |
Union Bank Of India Creation Date: 08 Sep 2001 | ₹1.25 Cr | Open |
Union Bank Of India Creation Date: 09 Feb 2000 | ₹9.50 M | Open |
How Many Employees Work at Erythro Pharma?
Erythro Pharma has a workforce of 33 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Erythro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Erythro Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
